Axsome Therapeutics

General Information

 We are a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system, or CNS, disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05, which we are developing for multiple indications. We recently initiated a Phase 3 trial with AXS-02 in complex regional pain syndrome and plan to initiate a Phase 3 trial with AXS-05 in treatment resistant depression in or before the first quarter of 2016.

Employees: 9
Founded: 2012
Contact Information
Address 25 Broadway, 9th Floor, New York, NY 10004, US
Phone Number (212) 332-3241
Web Address
View Prospectus: Axsome Therapeutics
Financial Information
Market Cap $172.26mil
Revenues $0.0 mil (last 12 months)
Net Income $-10.3 mil (last 12 months)
IPO Profile
Symbol AXSM
Exchange NASDAQ
Shares (millions): 5.7
Price range $9.00 - $9.00
Est. $ Volume $51.3 mil
Manager / Joint Managers Ladenburg Thalmann/ Cantor Fitzgerald & Co.
CO-Managers Brean Capital
Expected To Trade: 11/19/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change